Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Bufexamac | hsa00030 | Pentose phosphate pathway | 1.69E-02 | 2 | P60891, P37837 | PRPS1, TALDO1 | More | | Bufexamac | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Bufexamac | hsa00310 | Lysine degradation | 2.59E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Bufexamac | hsa00512 | Mucin type O-glycan biosynthesis | 3.19E-03 | 3 | O95395, Q8N4A0, Q9NY28 | GCNT3, GALNT4, GALNT8 | More | | Bufexamac | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Bufexamac | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Bufexamac | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Bufexamac | hsa00600 | Sphingolipid metabolism | 2.68E-02 | 2 | P07602, Q13510 | PSAP, ASAH1 | More | | Bufexamac | hsa00630 | Glyoxylate and dicarboxylate metabolism | 9.21E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Bufexamac | hsa00830 | Retinol metabolism | 4.55E-02 | 1 | P00325 | ADH1B | More | | Bufexamac | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Bufexamac | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.78E-02 | 2 | O95363, Q15046 | FARS2, KARS | More | | Bufexamac | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Bufexamac | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Bufexamac | hsa01230 | Biosynthesis of amino acids | 3.59E-02 | 3 | P60891, Q99707, P37837 | PRPS1, MTR, TALDO1 | More | | Bufexamac | hsa01522 | Endocrine resistance | 4.55E-02 | 5 | P14780, P22694, Q9UM47, P10415, Q13323 | MMP9, PRKACB, NOTCH3, BCL2, BIK | More | | Bufexamac | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Bufexamac | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | | Bufexamac | hsa03013 | RNA transport | 3.08E-05 | 13 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, EIF4B, TACC3 | More | | Bufexamac | hsa03040 | Spliceosome | 6.48E-07 | 14 | Q14562, O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Bufexamac | hsa04014 | Ras signaling pathway | 7.47E-04 | 11 | P42338, P20827, Q9NRA1, P49767, Q13009, Q7LDG7, P0DP23, P62873, P63218, P50151, P19174 | PIK3CB, EFNA1, PDGFC, VEGFC, TIAM1, RASGRP2, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | Bufexamac | hsa04015 | Rap1 signaling pathway | 1.79E-02 | 8 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | Bufexamac | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Bufexamac | hsa04062 | Chemokine signaling pathway | 4.82E-06 | 18 | P25024, P25025, P09341, P19875, P09769, P07948, P42338, P19174, P62873, P63218, P50151, P43250, Q7LDG7, Q13009, P14598, P42224, P25963, Q8WYR1 | CXCR1, CXCR2, CXCL1, CXCL2, FGR, LYN, PIK3CB, PLCG1, GNB1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, NCF1, STAT1, NFKBIA, PIK3R5 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q13547 | HDAC1 | Histone deacetylase 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.803 | Q13547 | HDAC1 | Histone deacetylase 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | -0.719 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P09769 | FGR | Tyrosine-protein kinase Fgr | 0.796 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.782 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.971 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.869 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.82 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.703 | Q13547 | HDAC1 | Histone deacetylase 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.864 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.704 | Q13547 | HDAC1 | Histone deacetylase 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.716 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43250 | GRK6 | G protein-coupled receptor kinase 6 | 0.818 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | -0.746 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | 0.706 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P14598 | NCF1 | Neutrophil cytosol factor 1 | 0.785 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.783 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.818 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q8WYR1 | PIK3R5 | Phosphoinositide 3-kinase regulatory subunit 5 | 0.752 |
| Bufexamac | hsa04064 | NF-kappa B signaling pathway | 5.98E-07 | 18 | P10415, Q13489, P25963, P51617, O00463, P14778, P01375, P19174, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q13315, P24522, P09341, P19875, Q06643 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, IL1R1, TNF, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | | Bufexamac | hsa04070 | Phosphatidylinositol signaling system | 2.93E-02 | 4 | P19174, P0DP23, P23743, P27987 | PLCG1, CALM1, DGKA, ITPKB | More | | Bufexamac | hsa04071 | Sphingolipid signaling pathway | 4.16E-06 | 10 | P17252, P21453, Q9H228, P01375, Q13510, Q13362, Q9BX95, Q16539, P10415, Q9UQC2 | PRKCA, S1PR1, EDG8, TNF, ASAH1, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2 | More | | Bufexamac | hsa04072 | Phospholipase D signaling pathway | 7.43E-03 | 8 | P42338, Q9UQC2, P43657, P25024, P25025, P19174, Q8WYR1, Q08828 | PIK3CB, GAB2, P2RY5, CXCR1, CXCR2, PLCG1, PIK3R5, ADCY1 | More | | Bufexamac | hsa04080 | Neuroactive ligand-receptor interaction | 1.11E-03 | 8 | P08311, Q15722, P21453, Q9H228, O00398, P21462, P21730, Q16581 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, C3AR1 | More | | Bufexamac | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Bufexamac | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Bufexamac | hsa04140 | Autophagy - animal | 4.55E-02 | 5 | P22694, Q14643, P10415, Q9H1Y0, Q04759 | PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | Bufexamac | hsa04141 | Protein processing in endoplasmic reticulum | 8.60E-03 | 6 | P30101, P60604, P11142, P08238, Q9H173, Q9UNL2 | PDIA3, UBE2G2, HSPA8, HSP90AB1, SIL1, SSR3 | More | | Bufexamac | hsa04145 | Phagosome | 2.51E-05 | 12 | O75015, P11215, Q15080, P14598, Q71U36, Q13509, P68371, Q13488, P05164, O60603, P35443, P13765 | FCGR3B, ITGAM, NCF4, NCF1, TUBA1A, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Bufexamac | hsa04151 | PI3K-Akt signaling pathway | 5.02E-03 | 16 | P42338, P43657, O43521, P20827, P49767, Q13362, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P23458, Q6ZUJ8, P30281 | PIK3CB, P2RY5, BCL2L11, EFNA1, VEGFC, PPP2R5C, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, JAK1, PIK3AP1, CCND3 | More | | Bufexamac | hsa04210 | Apoptosis | 1.52E-02 | 9 | Q13315, P10415, Q13489, P25963, P01375, P24522, Q16548, Q13077, Q14643 | ATM, BCL2, BIRC3, NFKBIA, TNF, GADD45A, BCL2A1, TRAF1, ITPR1 | More | | Bufexamac | hsa04213 | Longevity regulating pathway - multiple species | 1.36E-03 | 6 | P42338, Q9Y4H2, Q08828, P0DMV8, P11142, Q13547 | PIK3CB, IRS2, ADCY1, HSPA1A, HSPA8, HDAC1 | More | | Bufexamac | hsa04270 | Vascular smooth muscle contraction | 2.68E-02 | 3 | Q08828, P35579, P35318 | ADCY1, MYH9, ADM | More | | Bufexamac | hsa04340 | Hedgehog signaling pathway | 3.46E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Bufexamac | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Bufexamac | hsa04371 | Apelin signaling pathway | 3.84E-05 | 10 | P62873, P63218, P50151, Q8WYR1, Q13370, Q14814, Q14344, Q13485, P84022, P0DP23 | GNB1, GNG5, GNG10, PIK3R5, PDE3B, MEF2D, GNA13, SMAD4, SMAD3, CALM1 | More | | Bufexamac | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Bufexamac | hsa04540 | Gap junction | 1.08E-02 | 4 | Q13509, P68371, Q71U36, Q9NRA1 | TUBB3, TUBB2C, TUBA1A, PDGFC | More | | Bufexamac | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | Bufexamac | hsa04611 | Platelet activation | 1.42E-02 | 3 | Q9Y490, Q08828, Q8WYR1 | TLN1, ADCY1, PIK3R5 | More | | Bufexamac | hsa04612 | Antigen processing and presentation | 2.40E-02 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Bufexamac | hsa04613 | Neutrophil extracellular trap formation | 3.91E-07 | 20 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Bufexamac | hsa04621 | NOD-like receptor signaling pathway | 1.86E-05 | 16 | Q16539, Q14643, P23458, P25963, Q9H3M7, Q13489, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P49913, P12838 | MAPK14, ITPR1, JAK1, NFKBIA, TXNIP, BIRC3, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, CAMP, DEFA4 | More | | Bufexamac | hsa04623 | Cytosolic DNA-sensing pathway | 2.59E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Bufexamac | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | Bufexamac | hsa04650 | Natural killer cell mediated cytotoxicity | 2.48E-03 | 8 | P19174, P06239, O60880, P20963, P42338, Q13241, P26718, O14931 | PLCG1, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3 | More | | Bufexamac | hsa04657 | IL-17 signaling pathway | 3.91E-02 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Bufexamac | hsa04658 | Th1 and Th2 cell differentiation | 1.54E-05 | 13 | Q04759, P07766, P20963, P09693, Q16539, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Bufexamac | hsa04659 | Th17 cell differentiation | 3.46E-06 | 13 | P25963, Q04759, P19174, P06239, P42224, P14784, P14778, Q9UL17, P84022, Q13485, P08238, P07766, P20963 | NFKBIA, PRKCQ, PLCG1, LCK, STAT1, IL2RB, IL1R1, TBX21, SMAD3, SMAD4, HSP90AB1, CD3E, CD247 | More | | Bufexamac | hsa04660 | T cell receptor signaling pathway | 7.14E-06 | 17 | P01375, P25963, Q9UDY8, Q04759, P42338, P10747, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, NFKBIA, MALT1, PRKCQ, PIK3CB, CD28, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Bufexamac | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Bufexamac | hsa04664 | Fc epsilon RI signaling pathway | 7.41E-05 | 7 | P04141, P42338, Q9UQC2, P07948, P19174, P09917, P20292 | CSF2, PIK3CB, GAB2, LYN, PLCG1, ALOX5, ALOX5AP | More | | Bufexamac | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 5 | O75015, P06396, O14494, P14598, P17252 | FCGR3B, GSN, PLPP1, NCF1, PRKCA | More | | Bufexamac | hsa04668 | TNF signaling pathway | 2.59E-02 | 7 | P01375, O00463, Q13489, P25963, P20749, Q13077, P14780 | TNF, TRAF5, BIRC3, NFKBIA, BCL3, TRAF1, MMP9 | More | | Bufexamac | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Bufexamac | hsa04713 | Circadian entrainment | 2.18E-02 | 4 | P0DP23, P62873, P63218, P50151 | CALM1, GNB1, GNG5, GNG10 | More | | Bufexamac | hsa04724 | Glutamatergic synapse | 1.57E-02 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Bufexamac | hsa04726 | Serotonergic synapse | 3.80E-02 | 4 | P62873, P63218, P50151, P09917 | GNB1, GNG5, GNG10, ALOX5 | More | | Bufexamac | hsa04727 | GABAergic synapse | 4.18E-03 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Bufexamac | hsa04730 | Long-term depression | 4.86E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Bufexamac | hsa04744 | Phototransduction | 9.21E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Bufexamac | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Bufexamac | hsa04915 | Estrogen signaling pathway | 1.02E-02 | 3 | Q08828, P0DMV8, Q15788 | ADCY1, HSPA1A, NCOA1 | More | | Bufexamac | hsa04920 | Adipocytokine signaling pathway | 4.49E-02 | 4 | P25963, P33121, Q04759, P01375 | NFKBIA, ACSL1, PRKCQ, TNF | More | | Bufexamac | hsa04921 | Oxytocin signaling pathway | 3.76E-02 | 3 | Q08828, Q96RR4, Q8WYR1 | ADCY1, CAMKK2, PIK3R5 | More | | Bufexamac | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Bufexamac | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.21E-02 | 5 | P84022, Q13485, P42338, P49767, P19174 | SMAD3, SMAD4, PIK3CB, VEGFC, PLCG1 | More | | Bufexamac | hsa04940 | Type I diabetes mellitus | 4.18E-02 | 3 | P10747, P13765, P01375 | CD28, HLA-DOB, TNF | More | | Bufexamac | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Bufexamac | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Bufexamac | hsa04970 | Salivary secretion | 4.49E-02 | 4 | P22694, Q14643, P17252, P49913 | PRKACB, ITPR1, PRKCA, CAMP | More | | Bufexamac | hsa04972 | Pancreatic secretion | 4.73E-02 | 2 | Q08828, P62491 | ADCY1, RAB11A | More | | Bufexamac | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Bufexamac | hsa05012 | Parkinson disease | 1.77E-02 | 6 | P60604, P19174, P0DP23, Q71U36, Q13509, P68371 | UBE2G2, PLCG1, CALM1, TUBA1A, TUBB3, TUBB2C | More | | Bufexamac | hsa05032 | Morphine addiction | 2.18E-02 | 4 | P62873, P63218, P50151, Q13370 | GNB1, GNG5, GNG10, PDE3B | More | | Bufexamac | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Bufexamac | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 7.88E-05 | 8 | P25963, Q13488, P09341, P19875, P19174, P25024, P25025, P07948 | NFKBIA, TCIRG1, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Bufexamac | hsa05130 | Pathogenic Escherichia coli infection | 3.19E-02 | 6 | Q71U36, P16333, Q13509, P68371, Q14344, P25963 | TUBA1A, NCK1, TUBB3, TUBB2C, GNA13, NFKBIA | More | | Bufexamac | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Bufexamac | hsa05132 | Salmonella infection | 2.78E-03 | 16 | P51617, P25963, P01375, P08238, Q9UJU2, Q13489, P10415, O75369, Q96A32, O60603, Q9BQS8, Q13561, Q71U36, Q13509, P68371, P49754 | IRAK1, NFKBIA, TNF, HSP90AB1, LEF1, BIRC3, BCL2, FLNB, MYLPF, TLR2, FYCO1, DCTN2, TUBA1A, TUBB3, TUBB2C, VPS41 | More | | Bufexamac | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | Bufexamac | hsa05134 | Legionellosis | 1.49E-03 | 5 | P25963, P11215, P11142, P09341, P19875 | NFKBIA, ITGAM, HSPA8, CXCL1, CXCL2 | More | | Bufexamac | hsa05140 | Leishmaniasis | 3.90E-06 | 12 | P13612, O75015, P14598, P11215, P42224, P13765, O60603, P25963, P01375, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, ITGAM, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, MAPK14, IRAK1, NCF4 | More | | Bufexamac | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Bufexamac | hsa05144 | Malaria | 3.09E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Bufexamac | hsa05145 | Toxoplasmosis | 1.58E-03 | 10 | P51617, P25963, P01375, P10415, Q13489, P23458, P13765, Q8WYR1, P0DMV8, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, JAK1, HLA-DOB, PIK3R5, HSPA1A, TLR2 | More | | Bufexamac | hsa05146 | Amoebiasis | 7.41E-05 | 12 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | Bufexamac | hsa05150 | Staphylococcus aureus infection | 1.65E-02 | 6 | P21730, P21462, O75015, P13765, Q16581, P49913 | C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, CAMP | More | | Bufexamac | hsa05152 | Tuberculosis | 8.50E-04 | 10 | Q13488, O75015, P48382, O60603, P01375, P10415, P13765, P49913, Q9UDY8, P51617 | TCIRG1, FCGR3B, RFX5, TLR2, TNF, BCL2, HLA-DOB, CAMP, MALT1, IRAK1 | More | | Bufexamac | hsa05161 | Hepatitis B | 2.33E-02 | 8 | P17252, P14780, P25963, P01375, P10415, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, TNF, BCL2, IRAK1, TLR2, STAT4 | More | | Bufexamac | hsa05162 | Measles | 2.68E-02 | 2 | P23458, P0DMV8 | JAK1, HSPA1A | More | | Bufexamac | hsa05163 | Human cytomegalovirus infection | 2.56E-03 | 8 | P25963, P62873, P63218, P50151, P0DP23, Q14344, P30101, P01568 | NFKBIA, GNB1, GNG5, GNG10, CALM1, GNA13, PDIA3, IFNA21 | More | | Bufexamac | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 8.62E-05 | 10 | P01568, P42224, P25963, P62873, P63218, P50151, P19174, P07948, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, GNB1, GNG5, GNG10, PLCG1, LYN, CSF2, CALM1 | More | | Bufexamac | hsa05168 | Herpes simplex virus 1 infection | 3.79E-02 | 9 | P25963, P01568, P42224, Q07955, Q01130, Q13243, P30101, Q13398, O75820 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, PDIA3, ZNF211, ZNF189 | More | | Bufexamac | hsa05170 | Human immunodeficiency virus 1 infection | 4.52E-05 | 20 | P62873, P63218, P50151, P0DP23, P01375, P17252, O00463, P30101, Q14643, P01568, P51617, P25963, O60603, Q13315, O95067, P19174, P10415, Q13619, Q93034, Q9Y6Q5 | GNB1, GNG5, GNG10, CALM1, TNF, PRKCA, TRAF5, PDIA3, ITPR1, IFNA21, IRAK1, NFKBIA, TLR2, ATM, CCNB2, PLCG1, BCL2, CUL4A, CUL5, AP1M2 | More | | Bufexamac | hsa05200 | Pathways in cancer | 8.64E-05 | 23 | Q13751, P42338, P08238, P42224, P25963, P19174, P43246, P84022, Q13485, P20585, Q13547, P30281, P49767, P43657, P62873, P63218, P50151, Q14344, Q7LDG7, O75293, P0DP23, P01568, P14784 | LAMB3, PIK3CB, HSP90AB1, STAT1, NFKBIA, PLCG1, MSH2, SMAD3, SMAD4, MSH3, HDAC1, CCND3, VEGFC, P2RY5, GNB1, GNG5, GNG10, GNA13, RASGRP2, GADD45B, CALM1, IFNA21, IL2RB | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 1 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.783 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.818 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.869 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.816 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | -0.77 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P20585 | MSH3 | DNA mismatch repair protein Msh3 | 0.825 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.82 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.703 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.704 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | -0.756 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.742 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P0DP23 | CALM1 | Calmodulin-1 | 0.775 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P01568 | IFNA21 | Interferon alpha-21 | -0.733 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.717 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 |
| Bufexamac | hsa05202 | Transcriptional misregulation in cancer | 1.80E-06 | 18 | Q12778, Q15532, Q13315, P14780, P27930, P14923, Q15744, Q16548, Q13489, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P12980, P24522 | FOXO1, SS18, ATM, MMP9, IL1R2, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, LYL1, GADD45A | More | | Bufexamac | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Bufexamac | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Bufexamac | hsa05212 | Pancreatic cancer | 4.73E-03 | 5 | P42338, P42224, P84022, Q13485, O75293 | PIK3CB, STAT1, SMAD3, SMAD4, GADD45B | More | | Bufexamac | hsa05214 | Glioma | 4.75E-02 | 3 | P0DP23, P19174, O75293 | CALM1, PLCG1, GADD45B | More | | Bufexamac | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | Bufexamac | hsa05222 | Small cell lung cancer | 2.79E-02 | 6 | Q13489, P10415, P25963, Q13077, O00463, P24522 | BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A | More | | Bufexamac | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.27E-03 | 6 | P42338, P19174, P07766, P20963, P06239, Q04759 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ | More | | Bufexamac | hsa05310 | Asthma | 1.53E-04 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Bufexamac | hsa05321 | Inflammatory bowel disease | 5.03E-06 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Bufexamac | hsa05322 | Systemic lupus erythematosus | 2.54E-05 | 13 | O75015, P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, O60814, P68431, P05455 | FCGR3B, ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, SSB | More | | Bufexamac | hsa05332 | Graft-versus-host disease | 7.12E-05 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Bufexamac | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | |